Tested.
Tailored.
Guided.
Tested.
Tailored.
Guided.
Whenever possible, treatment should be informed by the patient’s individual biology.
Pathway Bio is a functional precision medicine company redefining how cancer treatment decisions are made.By combining multiomic profiling, AI-driven prediction, and our ex vivo microcancer technology, we help clinicians validate therapies on the patient’s own tumor — before treatment begins. This enables faster, more confident, and truly individualized care, even for the hard-to-treat cancers.
a revolutionary class of immunotherapy elicits responses in only about 20–40% of cancer, meaning large number of people do not respond (depending on therapy / cancer treatment) Citation: Nature Cancer (2022)
Roughly 90% of cancer therapies, including immunotherapies fail somewhere in clinical development due to factors including heterogeneith, resistance and safety profiles of the drug.
oncologists say treatment selection often relies on trial and error. Physicians are left with limited real-world insight before prescribing.
of US patients with cancer are NOT eligible for checkpoint inhibitor drugs. Source: JAMA Oncology, 2019
Our journey starts with a patient biopsy.
We integrate multimodal data to understand the biology of the tumor to predict the best therapy options to screen.
We screen our drugs in this high-fidelity model in 6-10 days.
Clinicians can be guided on their therapy strategies and talk to the data for insights.
Redefining precision medicine
ARTICLE
Pathway Bio is building a functional precision medicine platform to predict which therapies will be most effective for individual patients. We spoke to its CEO and co-founder Bobby Kaura about his experiences of launching the start-up and the KQ Labs entrepreneurial programme.
Evaluation of tumor response
PUBLICATION
Only 20 percent of renal and bladder cancer patients will show a signicant response to immune checkpoint inhibitor (ICI) therapy, and no test currently available accurately predicts ICI response.
Comprehensive Genomic Analysis
PUBLICATION
To select optimal therapies based on the detection of actionable genomic alterations in tumor samples is a major challenge in precision medicine.
